SLNO Form 4: Chief Business Officer awarded RSUs and options

Rhea-AI Filing Summary

Soleno Therapeutics (SLNO) reported an equity award and option activity for its Chief Business Officer. On 11/17/2025, the officer acquired 14,286 restricted stock units (RSUs) of common stock at a price of $0, all held directly after the transaction. Each RSU represents the right to receive one share of common stock.

One-half of these RSUs will vest on November 17, 2026, with one third of the remaining units vesting on each one-year anniversary after that, as long as the officer continues as a service provider. The filing also shows an employee stock option covering 64,286 shares of common stock at an exercise price of $47.25 per share, expiring on 11/17/2035. One-fourth of the option shares will vest on November 17, 2026, and one forty-eighth of the shares will vest monthly thereafter, subject to continued service.

Insider Trade Summary

64,286 shares exercised/converted

Mixed 2 txns

Insider Norrett Kevin

Role Chief Business Officer

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	64,286	$0.00	--
Grant/Award	Common Stock	14,286	$0.00	--

Holdings After Transaction: Employee stock option (right to buy) — 64,286 shares (Direct); Common Stock — 14,286 shares (Direct)

Footnotes (1)

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 17, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. One-fourth of the shares subject to the option shall vest on November 17, 2026 and one forty-eighth of the shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norrett Kevin

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		A		14,286(1)	A	$0	14,286(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$47.25	11/17/2025		M		64,286		(2)	11/17/2035	Common Stock	64,286	$0	64,286	D

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 17, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

2. One-fourth of the shares subject to the option shall vest on November 17, 2026 and one forty-eighth of the shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

	/s/ Anish Bhatnagar, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Soleno Therapeutics (SLNO) report for its Chief Business Officer?

The Chief Business Officer received 14,286 RSUs of Soleno Therapeutics common stock at $0 and holds an employee stock option for 64,286 shares at an exercise price of $47.25 per share.

When do the 14,286 RSUs for SLNO's Chief Business Officer vest?

One-half of the 14,286 RSUs vest on November 17, 2026. One third of the remaining RSUs will vest on each one-year anniversary thereafter, if the officer continues as a service provider.

What is the vesting schedule for the 64,286 stock options reported by Soleno Therapeutics (SLNO)?

For the 64,286 stock options, one-fourth of the shares vest on November 17, 2026, and one forty-eighth of the shares vest each month after that date, subject to continued service.

What is the exercise price and expiration date of the SLNO employee stock option?

The employee stock option has an exercise price of $47.25 per share and an expiration date of 11/17/2035, with 64,286 underlying shares of common stock.

What role does the reporting person hold at Soleno Therapeutics (SLNO)?

The reporting person is an officer of Soleno Therapeutics, serving as the company’s Chief Business Officer, and holds the reported securities directly.

Are the RSUs and stock options reported for SLNO subject to continued service conditions?

Yes. Both the RSUs and the stock options vest only if the reporting person continues to be a service provider under Soleno’s 2014 Equity Incentive Plan through each relevant vesting date.